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Abstract
This paper presents the experimental results establishing the lethal dose (LD) of the two products considered 
to have antitumor effect:Tumolit and Artemisinin.
For testing, we used an experimental design including two species of gnawers, Swiss mice and Wistar rats. 
Two experimental groups were used, consisting of 20 Swiss male mice each, as well as two groups of 10 Wistar 
rats/lot. In interpreting the results of the research and in the development of the experimental protocol, we took 
into account the toxicity scale after Hodge and Sterner. Initial doses were usedof both products at 200mg / kg / 
body for each mouse and rat, respectively, administered orallyin single-doses. Between each oral dose, there was 
one day of rest in order to evaluate possible effects. As mentioned in theProtocol, the dose was increased to500mg 
dose / kg / body,then to 1000 mg / kg / body, 2000mg / kg / body and then to 5000 mg / kg / body. At this last dose, 
administration was disrupted in mice. For rats, doses were further increased in three innings to 5000 mg / kg / 
body, 15,000 mg / kg / body concerned 20,000 mg / kg / body in single oral dose.  The administration was done by 
gavage in a single dose. There were no toxicity effects reported at any dose level applied, which is why we conclude 
that the two products are practically non-toxic.
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INTRODUCTION
In this paper, we present the experimental 
results on the median lethal dose (LD
50
) of the 
two products considered to have antitumor effect: 
Tumolit and Artemisinin (producers ‘prospect- 
Parapharm, Cluj; Houet al., 2008; Lai et al., 2013, 
Das, 2015).
Artemisinin is the active substance in the plant 
Artemisia annua, known as sweet wormwood 
(Efferth and Kaina, 2010). From a chemical point 
of view, Artemisinin is a sesquiterpene lactone 
with an endoperoxide bridge composed of three 
isoprene units and a lactone ring (www.ebi.ac.uk).
Tumolit, a dietary supplement considered 
by producer (Parapharm Cluj) to have antitumor 
effect, has the following composition: arginine, 
vitamin C, L-phenylalanine, L-histidine, D, 
L-methionine, malic acid, L-tryptophan, adenine, 
L-tyrosine, vitamin B6, vitamin B2, biotin, 
iron , zinc, magnesium, manganese, copper, 
molybdenum, vanadium, nickel, boron, fluorine, 
cobalt (according to information provided by the 
producer - Parapharm Cluj).
The lethal dose (LD) indicates an acute 
toxicity of substances that enter the body orally 
or parenterally, representing the minimum dose 
of the substance that causes the death of an 
adult animal. The lethal dose is established on an 
animal experimental batch and marked with DL 
followed by an index - from 1 to 100- indicating 
the percentage of lethality, at a given time; the 
expression is in mg / kg body weight (Gofita, 
2011).
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The variation in individual response to lethal 
doses of a substance required input values (Danila 
et al., 1984): DL5 (DLM) = minimum lethal dose, 
LD
50
 (DML) = median lethal dose, DL
75
 = fatal dose, 
DL
100
 = maximum lethal dose (absolute lethal 
dose), DL
0
 = maximum tolerated dose (with toxic 
effects but not fatal), often used in practice, it isnot 
actually a lethal dose.
Typically, in order to express the acute toxicity 
of a substance, the LD
50
 category is used (mg / 
kg), because at this dose, individual reactivity 
differences are lower.This is a virtual value, 
obtained by statistical calculation, not a biological 
constant. Many factors can influence the toxicity, 
thus affecting the expression LD
50.
Such factors 
include animal breed, age and weight, the nature 
of food, environmental conditions, absence of 
feeding before performing the test, the method 
of administration, the volume and nature of 
conditioning the environment, duration of animal 
observation. Because of these variables, for many 
purposes it is sufficient only to determine the 
order of magnitude for LD
50
 (eg. between 5 and 50 
mg / kg body weight and 500 mg / kg, etc.), not the 
absolute value (Gofita, 2011). In relation to LD
50
 
we can classify and compare toxic substances.
Lethal dose 50 is usually determined on 
laboratory animals such as mice, rats, rabbits, 
guinea pigs.Although other tests are under 
development, which may, to some extent, replace 
the current form test, classical measures are still 
among the most important in measuring toxicity. 
Many events led to the implementation and further 
use of these tests, although the test population is 
significantly reduced compared to their original 
size (Encyclopaedia of Toxicology, 2014). Result 
evaluation for our research was done according 
to Hodge and Sterner toxicity scale shown below 
(tab.1). 
MATERIALS AND METHODS
In practice, a lethal dose is recognized 
according to three coordinates: - minimum- 
DL25, - medium – DL 50 and maximum- DL 100. In 
our research, we tried to establish LD
50
, which 
represents the dose at which death occurs in 50% 
of experimental animals.
The purpose of these measurements was 
to establish a possibly toxic or even lethal effect 
of the two products administered, Tumolit or 
Artemisinin, a dose-dependent effect.Knowing 
that toxicity depends on exposure to the toxic 
compound, and this is, in turn, determined by the 
dose and duration of exposure, we tried to assess 
this risk by establishing LD
50
 and monitoring all 
parameters that could, in some way, influence the 
average lethal dose determination. 
The material studied was Tumolit, a dietary 
supplement, and Artemisinin, regarded as having 
antitumor effect (Golenser et al., 2006).
For each type of supplement tested, there was 
one experimental group consisting of 20 mice 
of a Swiss variety and 10 Wistar male rats.The 
experimental groups were kept under identical 
conditions of temperature (22º ± 0.5º C) program 
of 12/12 hour light-dark, ad libidum feeding 
fodder, a granulated product provided by the 
Cantacuzino Institute, which has the following 
composition: corn, soybean meal, sunflower meal, 
calcium carbonate, calcium phosphate, amino 
acids, salt, vitamin-mineral premix and water ad 
libidum. Tests were conducted in the Quantum 
Pharm company laboratory, Cluj-Napoca.
As a novelty, in our research we used a toxicity 
test progressively, from low doses to high doses. 
The advantage of this method is that it reduces the 
number of units required for experimental testing, 




     
Tab.1. Hodge and Sterner Toxicity Scale- Group- Toxicity Degree DL
50
 - single oral dose/rat
Toxicity Group Toxicity Degree DL50 – single oral dose/rat1 extremely toxic under 1 mg /kg2 very toxic 1 - 50 mg /kg3 moderately toxic 50 - 500 mg /kg4 low toxicity 500 - 5 000 mg /kg5 practically nontoxic 5 000 - 15 000 mg /kg6 relatively nontoxic over 15 000 mg /kg
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The doses used were administered with a 
48-hour difference, considering that their effect 
will fade in this time.The experiment lasted 
nine days on mice and 11 days on rats. Tumolit 
administration, as well as the product Artemisinin 
doses / mice / rats as shown in Table 2.3 was 
made orally by esophageal gavage, the product 
was mixed with distilled water in the amount of 
0.5 ml / mouse and 1 ml / rat.The doses per day 
were: (tab.2) (Table 3)
During the test, the behaviour of individual 
groups and the experimental units was observed, 
in terms of clinical signs of intoxication and body 
weight by weighing.
RESULTS AND DISCUSSION
At an amount of 6 mg/mouse or 28 mg/rat 
in both Tumolit and Artemisinin, there were no 
reported changes in group or individual behaviour or appetite.
The same observations resulted at a dose of 30 
mg/mouse and 140 mg/rats, administered on day 
five and recorded until the seventh day, whereas 
Artemisinin, administered at 60 mg /mouse which 
corresponds to 2000mg / kg / body, and 280 mg 
/ rat, in both species led to a tremor manifested 
by continuous motion in the first two hours 
following administration.There were no other 
events typical of a chemical poisoning, whereas 
the appetite was normal, although we found a 
slight reduction in weight for all individuals.The 
signs of agitation disappeared in the first 24 hours 
after administration, and in the next 24 hours, 
the behaviour returned to normal.The same signs 
and behaviours can be reported in Artemisinin 
to an amount of 150 mg/700 mg for mice/rats, 
respective.Tumolit did not lead to behavioural 
changes or weight loss.There were no clinical 
signs of intoxication with any of the products administered.
During the 11 days of the experiment there 
was no mortality. After testing, both groups 
of mice and rats were observed for 14 days to 
determine if any signs of late intoxication could 
occur.During this period the same type of feed 
was administered, we used the same conditions 
of light, temperature and water at discretion.In 
this interval, follow-up post-test animals exhibited 
normal behaviour without any clinical changes.







Obs.1. 200 mg 6 mg 28 mg Without clinical signs3. 500 mg 15 mg 70 mg Without clinical signs5. 1000 mg 30 mg 140 mg Without clinical signs
7. 2000 mg 60 mg 280 mg Without clinical signs
9. 5000 mg 150 mg 700 mg Without clinical signs11. 10,000 mg - 1400 mg Without clinical signs
Tab. 3. The doses of the product Artemisinin usedin the experiments  
Day Dose mg/kg/body Dose/Mice Swiss(mg) Dose/Rats Wistar(mg) Obs.1. 200 mg 6 mg 28 mg Without clinical signs3. 500 mg 15 mg 70 mg Without clinical signs5. 1000 mg 30 mg 140 mg Without clinical signs
7. 2000 mg 60 mg 280 mg
Agitation, without clinical 
signs, weight loss
9. 5000 mg 150 mg 700 mg
Agitation, without clinical 
signs, weight loss11. 10000 mg - 1400 mg Agitation, without clinical 
signs, weight loss
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CONCLUSIONS
1. The Tumolit product in the aforementioned dose 
did not produce any change in the experimental units.
2. The Artemisinin product determined, at the 
starting dose of 2000 mg / kg / body, mild 
manifestations of agitation, stagnation or slight 
reduction in body weight without any specific 
signs of intoxication.
3. We conclude that neither Tumolit, nor 
Artemisinin produce toxicity at a dose of 500 
mg / kg / body, which allows us to state that 
they present no toxicity.
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